Sign in Sign up for free

Edesa Biotech Est. EPS Q/Q

What is the Est. EPS Q/Q of Edesa Biotech?

The Est. EPS Q/Q of Edesa Biotech, Inc. is 44.44%

What is the definition of Est. EPS Q/Q?



Prospective quarterly EPS growth rate, year over year, is the estimated increase of the company’s EPS for the current quarter compared to performance from a past corresponding quarter.

= current quarter yoy (year over year)

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Est. EPS Q/Q of companies in the Health Care sector on NASDAQ compared to Edesa Biotech

What does Edesa Biotech do?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Companies with est. eps q/q similar to Edesa Biotech